Philogen SpA (MIL:PHIL) Total Operating Expense: €50.9 Mil (TTM As of Dec. 2025)


MIL:PHIL Philogen SpA MIL:PHIL
59 GF Score
Price €23.20
GF Value €227.78
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Philogen SpA Total Operating Expense?

Philogen SpA MIL:PHIL 59 Total Operating Expense is €50.9 Mil as of Dec. 2025. GuruFocus rates MIL:PHIL with a GF Score™ of 59/100 and a GF Value™ of €227.78 (Possible Value Trap). The stock has 3 warning signs investors should review.

Philogen SpA's Total Operating Expense for the six months ended in Dec. 2025 was €31.4 Mil. Philogen SpA's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €50.9 Mil.

Philogen SpA Total Operating Expense Related Terms

Philogen SpA Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Philogen SpA's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Philogen SpA Total Operating Expense Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 17.37 20.04 27.98 32.56 50.92

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.93 16.01 16.55 19.51 31.41
MIL:PHIL
59GF Score
Philogen SpA MIL:PHIL
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Philogen SpA Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €50.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €50.9 Mil mean?
Philogen SpA (MIL:PHIL) has a Total Operating Expense of €50.9 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Philogen SpA and its competitors.
Is Philogen SpA's Total Operating Expense too high?
Philogen SpA's current Total Operating Expense is €50.9 Mil. Overall, Philogen SpA has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Total Operating Expense compare to VRTX and REGN?
Philogen SpA's Total Operating Expense of €50.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Philogen SpA and its competitors. Philogen SpA's current Total Operating Expense is €50.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.78, compared to a current price of €23.20 — trading 89.8% below its estimated fair value. The current Total Operating Expense is €50.9 Mil. Philogen SpA's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Total Operating Expense is €50.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Philogen SpA (MIL:PHIL) Overvalued in 2026?

Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued. The current stock price of €23.20 is trading 89.8% below its estimated GF Value™ of €227.78. GuruFocus considers Philogen SpA to be Possible Value Trap.

Key valuation signals for MIL:PHIL:

  • Total Operating Expense: €50.9 Mil
  • GF Value™: €227.78 vs. price of €23.20 (89.8% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Philogen SpA Business Description

Other Exchanges 78Q:Germany
Address Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
59GF Score

Get the complete analysis for MIL:PHIL

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.20
Price
€227.78
GF Value